Verma: CMS working 'fast and furious' on IPI drug pricing model, but doesn't say when it will be released

Seema Verma
Centers for Medicare & Medicaid Services Administrator Seema Verma said that an international price index model is a "top priority" for her agency but didn't give a date on when it will be released. (YouTube)

The head of Medicare and Medicaid said a demonstration project to tie Medicare Part B prices to those prices paid overseas is a “top priority” despite delays in getting out a proposed rule.

Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma told reporters Thursday that “we are fast and furious on” getting out the proposed International Pricing Index (IPI) model.

Her comments come as other drug pricing initiatives by the Department of Health and Human Services (HHS) have been blocked or pulled.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

“It’s a top priority for my department,” Verma said of the IPI model.

HHS released an advanced notice of proposed rule-making last October outlining the program that targets certain physician-administered drugs paid for under Medicare Part B. HHS had planned to release the proposed rule by this spring and start the demonstration program by spring 2020, but so far no proposed rule has been released.

Verma declined to comment on the timeline for when a proposed rule would be released.

Currently, Part B pays the average sales price for a physician-administered drug, and the agency gives the doctor or hospital 6% of that price for handling and storage costs. Under the proposal, CMS would instead pay an index price based on international prices, which are normally far cheaper, and give providers an add-on fee for storage and handling.

The proposal has generated major opposition from the pharmaceutical industry group Pharmaceutical Research and Manufacturers of America, which called it a “socialized” program. Hospital groups, however, have been generally favorable to the proposal.

Verma’s comments come after a series of setbacks to the Trump administration’s efforts to combat high drug prices that were outlined in a blueprint released in May 2018.

A proposed rule to eliminate the safe harbor for Medicare Part D drug rebates was withdrawn after White House concerns it would raise premiums for seniors. A federal judge last month also blocked an HHS rule requiring drug manufacturers to post list prices on TV ads.

But the U.S. Food and Drug Administration has provided some bright spots for HHS in the form of record approvals of generic drugs to increase competition.

Suggested Articles

An estimated 73 million Americans with commercial health insurance face limited choices, according to a new American Medical Association study.

Absent adequate reimbursement for time spent on complex patient care, specialists are finding it harder to sustain their practices.

More than a year after Jonathan Bush stepped down as CEO of Athenahealth, he has landed a new gig as executive chairman of Firefly Health.